

Formulating Veterinary Tablets for Palatability and Acceptance

OBJECTIVE

To improve and promote palatability of solid oral dosage forms for companion animals.

BACKGROUND

There is a recognized need for highly palatable solid oral dosage forms for companion animals that are freely accepted from their feeding bowl or via the hand of the pet owner. Improving dosage forms to focus on the treatment regime, with convenience and compliance, represent a growing trend in companion animal formulations. This is especially true for medications administered for chronic conditions. Companies are also looking to meet marketing objectives such as product differentiation and customer loyalty.¹

In many cases, tablets and capsules dispensed to companion animals are given in a 'poke down' method or hidden in an attractive food. Commercially manufactured veterinary medicinal products (VMP) are often designed using 'human' formulation strategies. Although in many instances this works well, it doesn't address the specific needs for a veterinary dosage form. Chewable tablets may lack effective taste-masking of the drug substance and excipient selection can negatively impact palatability and voluntary acceptance.

FORMULATION

Many chewable tablet formulations intended for veterinary administration use a similar formulation approach with commonly used ingredients consisting of diluents, flavor, compressible sugars, flow aid, and lubricant. Other ingredients may include binders, animal/vegetable-sourced proteins, disintegrants, pigments, etc. For this study, a partially pregelatinized maize starch (Starch 1500®) was combined with microcrystalline cellulose (MCC), or MCC and lactose, at different ratios in a glucosamine tablet. To produce a chewable tablet of good hardness with low ejection force, low friability, and fast disintegration a ratio of Starch 1500 to MCC of 1:1 or 1:2 is recommended.

Process Flexibility

This strategy also provides manufacturing process flexibility without having to introduce new excipients to the formulation, enabling an easy move to granulation technologies like high shear and fluid bed.

To demonstrate, processing methods commonly used in the VMP industry were studied: top spray fluid bed granulation (FB), high shear granulation (HS), direct compression (DC), and roller compaction (RC) were used. The simplest manufacturing process is direct compression (DC), while wet granulation (FB and HS) are more complex multi-step methods.

Table 1. Glucosamine Tablet Formulation

Ingredient	Formula 1 (%)	Formula 2 (%)	Formula 3 (%)
Glucosamine HCL	30	30	30
Starch 1500	56	36	26
MCC	0	20	20
Lactose	0	0	10
Flavor	12	12	12
Mag Stearate	1	1	1
SiO2	1	1	1
Total	100	100	100

Batch Manufacturing

For each trial, a 3 kg batch size of the formulation was prepared. Fluid bed (FB) trials were conducted in a Freund-Vector VFC-3 fluid bed system with a 12 L container. The amount of water added and the spray rate was kept consistent across the formulations.

High shear granulation (HS) was completed in a Freund-Vector GMX-B 10 L bowl. Power consumption (KW) was used as an endpoint determination for each trial batch.

Following granulation, each batch was wet-milled using a Quadro Co-Mil with a 0.5" square hole screen, and the resulting granules were dried in a VFC-3 fluid bed, with a 12 L drying container. Roller compaction (RC) was completed using a Freund-Vector TFC- 220 with standard serrated rolls. The resulting ribbons were milled using an in-line oscillating screen granulator with a 12-mesh screen.

For consistency through the test formulations and process technology, Starch 1500 was added to the dry blend. Excipients not critical to the granulation process (such as the flavor and lubricants) were excluded from the granulation process then added via a V-Blender post granulation. The DC blends were all blended using a V-Blender with an intensifier bar for 3 minutes.

Tablet Compression

Following the granulation and blending steps, each blend was compressed utilizing a Piccola B/D rotary tablet press fitted with 17 mm round concave D-tooling. Tablets were compressed to a target weight of 1000 mg with compression forces ranging from 25 to 45 kN to generate a compression profile. A paddle feeder was used on the turret and 50 rpm turret speed was used for all compression trials.

Tablet samples were collected at each compression force and the resulting tablets tested for hardness, tensile strength, friability, disintegration, assay, and dissolution.

Dissolution

Testing was performed in 900 mL of DI water at 37°C using USP Apparatus II (paddles) at 75 rpm for 60 minutes, with samples taken at 5, 10, 15, 20, 30, 45, and 60 minute intervals.

Table 2.

Glucosamine Assay and Dissolution Instrumental Conditions

Mobile Phase Flow	0.5 mL/minute	
Column Temperature	30°C	
Injection Volume	0.5 µL	
Runtime	3 minutes	
Detector Settings	Temperature	35°C
	Power Settings	1.0
	Data Collection Rate	5
	Filter Constant	10

Glucosamine assay and dissolution samples were analyzed on a Thermo Vanquish UHPLC system with charged aerosol detection. The chromatography was performed by HILIC separation using a Waters Acquity UPLC BEH, 50 mm x 2.1 mm, 1.7 µm column.

The mobile phase consisted of acetonitrile and 200 mM formate buffer, pH 3.65 in the ratio of 80:20 metered by the binary pump. The remaining instrument conditions are represented in Table 2.

Dissolution performance was similar for all formulas and all processing technologies, with the formulations releasing >90% of the glucosamine HCl in <5 minutes.

RESULTS

All formulations performed well in the two wet granulation processes (FB and HS), with each resulting in similar performance. As expected, the HS granulations were denser and larger than the FB granulations in particle size, with HS granulations being largely influenced by the post-granulation milling process.

Tablet Properties

The formulation had a large influence on the resulting hardness of the tablets, with those produced using a Starch 1500: MCC blend resulting in the range of 6-8 KP, across the manufacturing technologies.

All formulations exhibited adequate lubricity resulting in acceptable tablet ejection forces. As expected, the highest ejection forces were seen with formulations containing lactose. All tablets exhibited low friability when compressed at moderate to high compression forces, making them suitable for subsequent film coating, packaging, and handling. The tablets also demonstrated fast disintegration times of <5 minutes facilitating good dissolution of the active.

Figure 3. Tablet Properties - Hardness




Figure 4. Tablet Properties – Ejection Force




Figure 5. Tablet Properties - Friability




Figure 6. Tablet Properties – Disintegration Time





Figure 7. Tablet Properties - Dissolution Performance



CONCLUSION

Robust tablets were made for all formulations using different processing technologies, which offers maximum flexibility to formulators and manufacturers. Combining Starch 1500 with MCC in the formulation resulted in tablets with good hardness, low ejection force and friability, along with excellent disintegration properties and dissolution performance. This formulation strategy offers improved palatability and acceptance of a drug product or supplements for companion animals leading to better compliance and therapy outcomes.

When direct compression is not viable and formulators need to use wet granulation, specifically for active ingredients with low density and poor flow, the binding properties of Starch 1500 provide a distinct advantage in terms of quality, flowable granulations without the use of any polymer binders. The use of Starch 1500 provides formulation and process flexibility by enabling in-use ratio changes without the addition of new excipients, avoiding costly delays in late-stage development.

This formulation approach reduces manufacturing risk, eliminates the need for additional stability studies while resolving late-stage, post-field study formulation issues. As a naturally sourced excipient from identity-preserved non-GM corn and manufactured in dedicated GMP facilities, the use of Starch 1500 in veterinary dosage forms like chewable tablets and soft chews provides unique benefits for manufacturers.

REFERENCES

1. Thombre, A.G. (2004) Oral Delivery of Medications to Companion Animals: Palatability Considerations. *Advanced Drug Delivery Reviews*, 56, 1399-413.
2. Reviews, 56, 1399-413.
3. Aleo, M., Ross, S., Becskei, C., Coscarelli, E., King, V., Darling, M. and Lorenz, J. (2018) Palatability Testing of Oral Chewables in Veterinary Medicine for Dogs. *Open Journal of Veterinary Medicine*, 8, 107-118.
4. Petry, G., Fourie, J. and Wolken, S. (2014) Comparison of the Palatability of a New Flavoured Drontal® Plus Tablet (Drontal® Plus Treat 10 kg) and Milbemax® Chewable Tablets When Presented to Privately Owned Dogs *Open Journal of Veterinary Medicine*, 4, 163-169.
5. Committee for Medicinal Products for Veterinary Use (CVMP) (2014) Guideline on the Demonstration of Palatability of Veterinary Medicinal Products. European Medicines Agency, London, 1-7

The information contained herein, to the best of Colorcon, Inc.'s knowledge is true and accurate. Any recommendations or suggestions of Colorcon, Inc. with regard to the products provided by Colorcon, Inc. are made without warranty, either implied or expressed, because of the variations in methods, conditions and equipment which may be used in commercially processing the products, and no such warranties are made for the suitability of the products for any applications that you may have disclosed. Colorcon, Inc. shall not be liable for loss of profit or for incidental, special or consequential loss or damages.

Colorcon, Inc. makes no warranty, either expressed or implied, that the use of the products provided by Colorcon, Inc., will not infringe any trademark, trade name, copyright, patent or other rights held by any third person or entity when used in the customer's application.

For more information, contact your Colorcon representative or call:

North America
+1-215-699-7733

Europe/Middle East/Africa
+44 (0)-1322-293000

Latin America
+54-11-5556-7700

India
+91-832-6727373

China
+86-21-61982300

You can also visit our website at www.colorcon.com



© BPSI Holdings LLC, 2022.

The information contained in this document is proprietary to Colorcon, Inc. and may not be used or disseminated inappropriately.

All trademarks, except where noted, are property of BPSI Holdings LLC.

VetADS_St1500_V1_0402022